Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience

Author:

Ho I‐Wei12ORCID,Pan Yu‐Ling13,Lai Jiun‐I2456,Liu Chun‐Yu1257ORCID

Affiliation:

1. School of Medicine National Yang Ming Chiao Tung University Taipei Taiwan

2. Division of Medical Oncology, Department of Oncology Taipei Veterans General Hospital Taipei Taiwan

3. Department of Internal Medicine En Chu Kong hospital New Taipei city Taiwan

4. Institute of Clinical Medicine National Yang Ming Chiao Tung University Taipei Taiwan

5. Comprehensive Breast Health Center Taipei Veterans General Hospital Taipei Taiwan

6. Center of Immuno‐Oncology, Department of Oncology Taipei Veterans General Hospital Taipei Taiwan

7. Division of Transfusion Medicine, Department of Internal Medicine Taipei Veterans General Hospital Taipei Taiwan

Abstract

AbstractBackgroundThymic carcinoma is a rare disease with an incidence of around 0.5 cases per million with a poor prognosis. The aim of this study was to assess patient outcomes with advanced thymic carcinoma receiving first‐line chemotherapy.MethodsIn our retrospective cohort study, we included patients who underwent treatment for metastatic thymic carcinoma between January 2013 to December 2019 in our hospital. Overall survival, progression‐free survival (PFS), objective response rates (ORR) and chemotherapy regimens were assessed and analyzed.ResultsA total of 27 patients were retrospectively analyzed. All patients received a platinum (cisplatin or carboplatin) based regimen as first‐line chemotherapy (29.6% received ADOC, 11.1% received PE, 40.7% received CP, 14.8% received CAP). The median PFS on first‐line chemotherapy was 199 days. The response rate was 40.7%. Median overall survival (OS) was 585 days. Positive CD5 staining was associated with better PFS.ConclusionWe highlight the critical role of platinum‐based chemotherapy agents as a primary treatment modality in advanced thymic carcinoma, underscoring the efficacy of platinum as a first‐line option for recurrent disease, even in cases previously treated with platinum. Additionally, our findings indicate that CD5 positivity could be associated with improved PFS, suggesting its potential as a prognostic marker.

Funder

Taipei Veterans General Hospital

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3